deltatrials
Completed PHASE3 NCT00055679

Combination Chemotherapy in Treating Women With Stage I Breast Cancer

Phase III Randomized Study Of Adjuvant Fluourouracil, Epirubicin And Cyclophosphamide, In Women With Stage I Breast Cancer

Sponsor: UNICANCER

Conditions Breast Cancer
Interventions cyclophosphamide epirubicin hydrochloride fluorouracil
Updated 6 times since 2017 Last updated: Jun 17, 2013 Started: Aug 31, 2002 Primary completion: Jun 30, 2012 Completion: Jun 30, 2013

Listed as NCT00055679, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by UNICANCER, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UNICANCER
Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albi, France, Angers, France, Annecy, France, Argenteuil, France, Aulnay-sous-Bois, France, Auxerre, France, Avignon, France, Bayonne, France, Beauvais, France, Belfort, France and 51 more location s